HealthEli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China approved Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity. The National Medical Products Administration said Thursday that the once-daily drug, sold as Foundayo, can be used for chronic weight management by obese or overweight adults.
S
South China Morning Post★★★☆☆2026-11-13 01:01Original
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
Health